Humanigen [NASDAQ: HGEN] Receives Two Patents In US

Humanigen, Inc. [NASDAQ: HGEN] disclosed Tuesday it has received two patents from the US PTO. These two patents will grow the patent portfolio of the firm and determine the value of the firm’s revolutionary method to neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF).

Furthermore, the first patent which the firm has received titled Method of reducing the level of Non-GM-CSF Cytokines/Chemokines in immunotherapy-related toxicity. This patent was issued on January 26, 2021. The title of the second patent is the method of reducing the tumor relapse rate in immunotherapy by the administration of Lenzilumab. This patent was issued on February 23, 2021.

Shares of Humanigen, Inc. [NASDAQ: HGEN] went up 0.11% during the pre-market trading session of Tuesday. The firm’s share has fluctuated between the 52-week low range of $1.64 and a high range of $33.95. HGEN’s share has moved up 1024.01% from its 52-week low and moved down to -45.54% from its 52-week high. Humanigen, Inc. [NASDAQ: HGEN] market capitalization has stayed high, reaching $925.05 million at the time of writing.

The first patent which was granted to the firm is for the use of lenzilumab to decrease the non-GM-CSF cytokines/chemokines that add to immunotherapy-related toxicity. The second patent which was granted to the firm is for the use of lenzilumab to enhance the effectiveness and resilience of immunotherapy.